Management of multiple drug-resistant tuberculosis

Received 5 February 2002; accepted 29 May 2002.

Abstract

There has been a worldwide increase in multiple drug-resistant tuberculosis (MDR-TB) which has in the past been associated with a poor prognosis. In the U.K., about half of the cases live in the London area and we have set out to obtain further information on their treatment and outcome. We examined the risk factors, drug resistance, drug treatment, sputum conversion, and outcome in patients with MDR-TB at three hospitals in South London and diagnosed during the period June 1995–January 1999. Human Immunodeficiency Virus (HIV)-positive patients were excluded. There were 760 patients resident in Lambeth, Southwark and Lewisham Health Authority (LSLHA) who were notified as tuberculosis (TB) during the time period and who were of negative or unknown HIV status. (The population of LSLHA is approx. 750 000.) There was a total of 13 patients with MDR-TB, known or presumed to be HIV negative. Their median age was 28 years (range 15–53); nine (69%) were born outside the U.K. and 11 had pulmonary disease; they had organisms resistant to a median of two first-line drugs (range 2–4) and to a median of four of all drugs tested (range 2–10). They received treatment with a median of six drugs (range 3–9). Eight were followed up for at least 3 years (range 3–6) after the completion of treatment; at their last assessment none had features of active TB and all were sputum negative (smear and culture). Two returned to their countries of origin during treatment; they were sputum negative at that time. Two patients are well and continue on treatment in the U.K. One patient (known HIV negative) died following treatment failure. In conclusion, we obtained disease-free survival in eight cases of MDR-TB, known or presumed to be HIV negative and followed up for 3 years or more. The prognosis for patients treated at specialised centres is good (and better than is generally believed). We describe a new protocol for the detection and management of MDR-TB.

Keywords: tuberculosis, multiple drug resistant, risk factors, drug therapy, outcome.

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Abstract

• References

• Copyright

References

REFERENCES

1. 1 Espinal MA, Laszlo A, Simonsen L. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001;344:1294–1303. MEDLINE | CrossRef

2. 2 Fujiwara PI, Cook SV, Rutherford CM. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med. 1997;157:531–536. MEDLINE

3. 3 Irish C, Herbert J, Bennett D. Database study of antibiotic resistant tuberculosis in the United Kingdom, 1994-6. Br Med J. 1999;318:497–498.

4. 4 Public Health Laboratory Service, Communicable Disease Surveillance Centre, www.phls.co.uk

5. 5 Balogun MA, Wall PG, Noone A. Undernotification of tuberculosis in patients with AIDS. Int J STD AIDS. 1995;7:58–60. MEDLINE | CrossRef

6. 6 Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Engl J Med. 1993;328:527–532. MEDLINE | CrossRef

7. 7 Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995;333:907–911. MEDLINE | CrossRef

8. 8 Helbling P, Altpeter E, Raeber P-A, Pfyffer GE, Zellweger J-P. Surveillance of antituberculosis drug resistance in Switzerland 1995–1997: the central link. Eur Resp J. 2000;16:200–202.

9. 9 Thomsen VO, Bauer J, Lillebaek T, Glismann S. Results from 8 yrs of susceptibility testing of clinical Mycobacterium tuberculosis isolates in Denmark. Eur Resp J. 2000;15:203–208.

10. 10 Schwoebel V, Decludt B, de Benoist A-C. Multidrug resistant tuberculosis in France 1992–1994: two case-control studies. Br Med J. 1998;317:630–631.

11. 11 Borchardt J, Kirsten D, Jorres R, Kroeger C, Magnussen H. Drug-resistant tuberculosis in Northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993. Eur Resp J. 1995;8:1076–1083.

12. 12 Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. JAMA. 1993;270:65–68. MEDLINE

13. 13 Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784–791. MEDLINE | CrossRef

14. 14 Espinal MA, Laserson K, Camacho M. Determinants of drug-resistant tuberculosis: analysis of countries. Int J Tuberc Lung Dis. 2001;5:887–893. MEDLINE

15. 15 Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary TB resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis. 1998;2:877–884. MEDLINE

16. 16 Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:423–430. MEDLINE

17. 17 Thorax. 1998;53:536–548. MEDLINE | CrossRef

18. 18 Iseman MD. Management of multidrug-resistant tuberculosis. Chemotherapy. 1999;45:3–11. CrossRef

19. 19 Espinal MA, Kim SJ, Suarez PG. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2537–2545. MEDLINE | CrossRef

20. 20 Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus”. Br Med J. 1998;317:671–674.

21. 21 Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 1999;3:564–581. MEDLINE

22. 22 Drobniewski FA. Diagnosing multidrug resistant tuberculosis in Britain. Br Med J. 1998;317:1263–1264.

23. 23 Drobniewski F, Hutchison D CS. Multiple-drug-resistant tuberculosis. In: Finch RG editors. Bailliere's Clinical Infectious Diseases. 5:London: Baillére Tindall; 1999;.

a Department of Respiratory Medicine, King's College Hospital, London, U.K.

b PHLS Mycobacterium Reference Unit and Department of Respiratory Medicine, King's College Hospital, London, U.K.

c Department of Respiratory Medicine, Guy's and St Thomas' Hospitals, London, U.K.

f1 Correspondence should be addressed to: Dr D.C.S. Hutchison, Department of Respiratory Medicine, King's College Hospital, London SE5 9RS, U.K. Fax: +44 20 73 46 35 89

PII: S0954-6111(02)91412-5

doi:10.1053/rmed.2002.1412

11 of 18